Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 19, Issue 1, 2001, Pages 69-74

  Lee, Y J ^a   Shin, K C ^a   Kang, S W ^a   Lee, E B ^a   Kim, H A ^a   Song, Y W ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

PIIINP; SIL 2R; Systemic sclerosis; VWF

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 2 RECEPTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LABORATORY TEST; LUNG FUNCTION; MALE; MEASUREMENT; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SCORING SYSTEM; SERUM; SKIN DISEASE; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCINS; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-2; SCLERODERMA, SYSTEMIC; SOLUBILITY; VON WILLEBRAND FACTOR;

EID: 0035098549     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pathogenesis of systemic sclerosis (scleroderma)
2. Type III collagen aminopeptide levels in serum of patients with progressive systemic scleroderma
3. Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: Relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites
4. Serum type III pro-collagen peptide concentration in systemic sclerosis and Raynaud's phenomenon: Relationship to disease activity and duration
5. Serum level of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis
6. Pathogenetic and clinical significance of fibroblast activation in scleroderma lung disease
7. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar larvage fluid from patients with pulmonary fibrosis
8. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis: A follow-up investigations in subclasses and during therapy
9. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with sclerodema
10. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance
11. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil
12. Cytokine production and serum levels in systemic sclerosis
13. Immunologic parameters in systemic sclerosis
14. Soluble interleukin 2 receptors in patients with systemic sclerosis: Clinical and laboratory correlations
15. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma
16. Circulating interleukin 1 and soluble interleukin 2 receptor: Evaluation as markers of disease of activity in scleroderma
17. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: Effects on cutaneous fibrosis and interleukin 2 receptor levels
18. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon
19. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon
20. The clinical significance of coagulation abnormalities in systemic sclerosis
21. Elevated von Willebrand factor antigen in systemic sclerosis: Relationship to visceral disease
22. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis
23. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: A longitudinal study of plasma ACE level, endothelial injury and lung involvement
24. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
25. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
26. Autoantigenic epitopes on DNA topoisomerase I: Clinical and immunogenetic associations in systemic sclerosis
27. Systemic sclerosis (scleroderma): Clinical aspects
28. Racial differences in the frequencies of scleroderma-related autoantibodies
29. Association of HLA-DR genes with systemic sclerosis in Koreans
30. Association of HLA-DR with progressive systemic sclerosis in Japanese
31. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies
32. Serum III procollagen, but not serum I procollagen, is predictive of lung involvement in systemic sclerosis
33. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis
34. Lymphokine activated killer (LAK) cell activity in the peripheral blood lymphocytes of systemic sclerosis (SSc) patients
35. Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis